|Support type:||Scholarships in Brazil - Master|
|Effective date (Start):||May 01, 2016|
|Effective date (End):||February 28, 2017|
|Field of knowledge:||Health Sciences - Pharmacy|
|Principal Investigator:||Andrei Moroz|
|Grantee:||Rodrigo de Almeida|
|Home Institution:||Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil|
Prostate cancer (PCa) is the most common malignancy in men and the second leading cause of male cancer-related deaths in America and in the Western world. In Brazil, the estimated number of new cases was 68.800 for the year of 2014. The most lethal PCa form is the castration resistant prostate cancer (CRPC), for which available treatments grant median survival of 24 months for affected patients, however, there are no definite cure treatments for this form of prostate cancer. Currently, adjuvant therapies for chemotherapy and radiotherapy are of great relevance, immunotherapy being one of most importance, which employs monoclonal antibodies, tools that also have great value for diagnosis and staging of PCa. In this sense, this research project aims to obtain and characterize a panel of murine monoclonal antibodies directed specifically against human prostate tumor cells. Initially, a subtractive immunization will be performed in BALB/C mice using cyclophosphamide (RWPE-1 cell line as the tolerogen and LNCaP as the immunogen). After all the classical steps to obtain the hybridoma clones, these antibodies will have their class and subclass investigated and will be tested in human prostate tumor tissue stored at pathology services, to validate their diagnosis/staging applications. Finally, the best two monoclonal antibodies produced in this project will be studied at in vitro assays to screen for their potential direct antitumoral effects.